A neuroimaging biomarker for disease staging in clinically diagnosed Alzheimer’s disease

Authors:

Abstract
Precision medicine for Alzheimer’s disease (AD) requires the development of a robust management framework grounded in individualized disease staging
Funding Information
  • BUPT Excellent Ph.D. Students Foundation (No. CX2023117)
  • Natural Science Foundation of Beijing Municipality (No. 7244519)
  • National Natural Science Foundation of China (No. T2425027, No.62333002)

This publication has 50 references indexed in Scilit: